当使用靶向特异性口服抗凝剂的患者需要进行手术时。

When patients on target-specific oral anticoagulants need surgery.

作者信息

Anderson Mary, Hassell Kathryn L, Trujillo Toby C, Wolfe Brian

机构信息

Assistant Professor, Hospital Medicine Section, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora

Professor of Medicine, Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora.

出版信息

Cleve Clin J Med. 2014 Oct;81(10):629-39. doi: 10.3949/ccjm.81a.13168.

DOI:10.3949/ccjm.81a.13168

PMID:25274657

Abstract

The target-specific oral anticoagulants (TSOACs), eg, dabigatran, rivaroxaban, and apixaban, are changing the way we manage thromboembolic disease. At the same time, many clinicians wonder how best to manage TSOAC therapy when patients need surgery. An in-depth understanding of these drugs is essential to minimize the risk of bleeding and thrombosis perioperatively.

摘要

靶向特异性口服抗凝剂（TSOACs），如达比加群、利伐沙班和阿哌沙班，正在改变我们治疗血栓栓塞性疾病的方式。与此同时，许多临床医生想知道当患者需要手术时，如何最好地管理TSOAC治疗。深入了解这些药物对于将围手术期出血和血栓形成的风险降至最低至关重要。